Physician profile
George Linsenmeyer
NPI 1003842246
$1,742.46
in general payments reported to CMS, 2019-2025
22 companies · $64.09 in 2025
The $64.09 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $13.03 · 2021: $368 · 2022: $388 · 2023: $628 · 2024: $122 · 2025: $64.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $813.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $378.36 | 2019-2025 | |
| Abbott Laboratories | $286.47 | 2021-2022 | |
| Boston Scientific Corporation | $236.53 | 2022-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $150.62 | 2020-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $92.11 | 2023-2024 | Camzyos |
| Shockwave Medical, INC | $80.40 | 2022 | |
| Abiomed | $74.05 | 2021-2023 | Impella |
| Janssen Pharmaceuticals, INC | $68.46 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $63.81 | 2021-2023 | Verquvo |
| Pfizer INC. | $62.52 | 2022-2025 | |
| Impulse Dynamics (USA) INC. | $50.14 | 2023 | Optimizer |
| Amgen INC. | $41.17 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $27.59 | 2022 | |
| Sunovion Pharmaceuticals INC. | $20.91 | 2019 | |
| Cvrx, INC. | $19.51 | 2023 | Barostim Neo System |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.58 | 2023 | Jardiance |
| Medtronic, INC. | $14.31 | 2021 | |
| Kestra Medical Technology Services, INC. | $13.36 | 2023 | Assure Wcd |
| Kowa Pharmaceuticals America, INC. | $12.06 | 2019 | |
| Esperion Therapeutics, INC. | $11.80 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $11.39 | 2019 | |
| Astellas Pharma US INC | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Linsenmeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.